PROPEL® is the first and only device clinically shown to keep the sinuses open after surgery, precisely deliver anti-inflammatory medication directly into the healing tissues, then dissolve.
The innovative sinus stent decreases post-operative scarring and inflammation, reducing the need for additional surgical procedures as well as oral steroids and their potential side effects. At the same time, PROPEL's spring-like, lightweight design means patients cannot even tell its there.
The PROPEL Device is the first to combine structural support and medication in one.
1 Han JK, Marple BF, Smith TL et al. IFAR.2012; 2:271-279.
The PROPEL sinus implant is intended for use in patients ≥ 18 years of age following ethmoid sinus surgery to maintain the sinus opening. This product is not intended for people who are allergic to the drug (mometasone furoate) or to certain polymers. Safety and effectiveness of the implant in pregnant or nursing females has not been studied. Risks may include pain/pressure, movement of the implant (within or out of the sinus) and possible side effects of the drug. The most common side effects in clinical studies were infection, headache and nose bleed. For more information on the risks and benefits of PROPEL, please talk to your doctor. The FDA approved labeling can be found at www.PROPELOPENS.com.
Rx only. For additional patient information regarding sinusitis, visit: www.MySinusitis.com.
©2016 Intersect ENT, Inc. All rights reserved. INTERSECT and PROPEL are trademarks and registered trademarks of Intersect ENT, Inc.
MySinusitis.com is a trademark of Intersect ENT, Inc.